Suzhou Yilian Bio-Pharmaceutical Co
Latest round
- Series B
Last raised
- Mar 2022
Total raised
- $124M
Investors
- 7
About Suzhou Yilian Bio-Pharmaceutical Co
Founded in 2020 by CEO Xue Tongtong and based in China, Suzhou Yilian Bio-Pharmaceutical Co Ltd, also known as Yilian Biotechnology, operates as a biotechnology company that develops antibody conjugated drugs (ADC). Yilian Biotechnology develops antibody conjugated drugs to treat cancer cells and release a toxic drug into the cancer cell. The firm plans to use its Series A funds towards the development of its antibody conjugated drug (ADC) product pipeline and the establishment of a new conjugated drug research and development platform.
Who invested in Suzhou Yilian Bio-Pharmaceutical Co
7 investors across 2 rounds
See all investors in Suzhou Yilian Bio-Pharmaceutical Co
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Suzhou Yilian Bio-Pharmaceutical Co
Who invested in Suzhou Yilian Bio-Pharmaceutical Co?
Suzhou Yilian Bio-Pharmaceutical Co has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Suzhou Yilian Bio-Pharmaceutical Co raised?
Suzhou Yilian Bio-Pharmaceutical Co has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Suzhou Yilian Bio-Pharmaceutical Co last raise money?
Suzhou Yilian Bio-Pharmaceutical Co's most recent round on record is a Series B, in Mar 2022.
What does Suzhou Yilian Bio-Pharmaceutical Co do?
Founded in 2020 by CEO Xue Tongtong and based in China, Suzhou Yilian Bio-Pharmaceutical Co Ltd, also known as Yilian Biotechnology, operates as a biotechnology company that develops antibody conjugated drugs (ADC).
Where is Suzhou Yilian Bio-Pharmaceutical Co headquartered?
Suzhou Yilian Bio-Pharmaceutical Co is headquartered in China.
Which VCs invest in companies like Suzhou Yilian Bio-Pharmaceutical Co?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Suzhou Yilian Bio-Pharmaceutical Co's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Suzhou Yilian Bio-Pharmaceutical Co? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.